Replies to post #193 on Fate Therapeutics Inc (FATE)

[jondoeuk]

Testing a triplet makes sense. So, AFM24, an anti-PD(L)-1 and NKs. I know they are already testing a doublet https://www.globenewswire.com/en/news-release/2021/11/08/2329040/0/en/Affimed-and-NKGen-Biotech-Announce-Initiation-of-Patient-Recruitment-in-a-First-in-human-Phase-1-2a-Trial-of-Innate-Cell-Engager-AFM24-in-Combination-with-Autologous-NK-Cell-Produc.html

As for TAM flipper, if it shows single-agent activity in select indications, then yes.